Johan Hyllner
Overview
Explore the profile of Johan Hyllner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poch C, Foo K, De Angelis M, Jennbacken K, Santamaria G, Bahr A, et al.
Nat Cell Biol
. 2022 May;
24(5):659-671.
PMID: 35550611
Heart regeneration is an unmet clinical need, hampered by limited renewal of adult cardiomyocytes and fibrotic scarring. Pluripotent stem cell-based strategies are emerging, but unravelling cellular dynamics of host-graft crosstalk...
2.
Williams D, Archer R, Archibald P, Bantounas I, Baptista R, Barker R, et al.
Regen Med
. 2016 Jul;
11(5):483-92.
PMID: 27404768
This paper summarizes the proceedings of a workshop held at Trinity Hall, Cambridge to discuss comparability and includes additional information and references to related information added subsequently to the workshop....
3.
Hyllner J, Mason C, Wilmut I
Philos Trans R Soc Lond B Biol Sci
. 2015 Sep;
370(1680):20150320.
PMID: 26416687
No abstract available.
4.
Mount N, Ward S, Kefalas P, Hyllner J
Philos Trans R Soc Lond B Biol Sci
. 2015 Sep;
370(1680):20150017.
PMID: 26416686
Cell therapies offer the promise of treating and altering the course of diseases which cannot be addressed adequately by existing pharmaceuticals. Cell therapies are a diverse group across cell types...
5.
Barry J, Hyllner J, Stacey G, Taylor C, Turner M
Curr Stem Cell Rep
. 2015 Jul;
1(2):110-117.
PMID: 26225325
The development of induced pluripotent stem cells offers the possibility of the scalable manufacture of cellular therapies for regenerative medicine. Moreover, donors can be selected on the basis of major...
6.
Bisson I, Green E, Sharpe M, Herbert C, Hyllner J, Mount N
Regen Med
. 2015 Apr;
10(2):169-79.
PMID: 25835481
Cell Therapy Clinical Trial and Preclinical Research databases have been established by the Cell Therapy Catapult to document current and future cell therapy clinical trials in the UK. We identified...
7.
Kaneko T, Nomura F, Hamada T, Abe Y, Takamori H, Sakakura T, et al.
Sci Rep
. 2014 Apr;
4:4670.
PMID: 24751527
To overcome the limitations and misjudgments of conventional prediction of arrhythmic cardiotoxicity, we have developed an on-chip in vitro predictive cardiotoxicity assay using cardiomyocytes derived from human stem cells employing...
8.
Borestrom C, Simonsson S, Enochson L, Bigdeli N, Brantsing C, Ellerstrom C, et al.
Stem Cells Transl Med
. 2014 Mar;
3(4):433-47.
PMID: 24604283
Human induced pluripotent stem cells (iPSCs) are potential cell sources for regenerative medicine; however, clinical applications of iPSCs are restricted because of undesired genomic modifications associated with most reprogramming protocols....
9.
Ellerstrom C, Strehl R, Hyllner J
Methods Mol Biol
. 2013 Apr;
997:239-51.
PMID: 23546761
Human pluripotent stem cells provide unique possibilities for in vitro studies of human cells in basic research, disease modeling as well as in industrial applications. By introducing relevant genome engineering...
10.
Li O, Tormin A, Sundberg B, Hyllner J, Le Blanc K, Scheding S
PLoS One
. 2013 Feb;
8(1):e55319.
PMID: 23383153
Mesenchymal stroma cells (MSCs) have a high potential for novel cell therapy approaches in clinical transplantation. Commonly used bone marrow-derived MSCs (BM-MSCs), however, have a restricted proliferative capacity and cultures...